Selected talks will be added to existing Major Symposia and Advances sessions, based on the subject matter of the abstract. Most talks will be 15 minutes in length plus 5 minutes for discussion, but the assigned length of the talk may vary depending on the session.
Applicants who are selected to give talks at the Annual Meeting will receive travel support and complimentary registration for the meeting.
Congratulations to the 2026 NextGen Stars!
CheukMan Cherie Au, PHD
Assistant Professor Weill Cornell Medicine, New York, New York First-in-class dual AR/AR-V7 molecular glue degraders targeting the undruggable N-terminal domain to overcome therapeutic resistance in prostate cancer
Daniel D. Azorín, PhD
Application Development Scientist ETH Zurich, Basel, Switzerland Screening for tumor microtube-targeting drugs identifies PKC modulators as multipotent inhibitors of glioblastoma progression
Jian Carrot-Zhang, PhD
Assistant Professor Memorial Sloan Kettering Cancer Center, New York, New York Understand germline determiants of cancer progression using multi-ancestral real-world data
Steven Corsello, MD
Assistant Professor Stanford University, Stanford, California Discovery of TRIM21 molecular glues that drive potent anti-tumor efficacy via nuclear pore complex degradation
Alvaro Curiel Garcia, PhD
Associate Research Scientist Columbia University Irving Medical Center, New York, New York BMAL2 as a KRAS-driven conductor of hypoxic adaptation and epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma
William Freed-Pastor, MD, PhD
Assistant Professor Dana-Farber Cancer Institute, Boston, Massachusetts Cancer-restricted cryptic antigens: Novel targets for next-generation T cell-based therapies
Adam Grippen, MD, PhD
Resident/Post-doctoral candidate UT MD Anderson Cancer Center, Houston, Texas Mechanisms by which mRNA vaccines augment responses to immune checkpoint blockade
Long Nguyen, MD, PhD
Postdoctoral Researcher University of Chicago, Chicago, Illinois BACH1 drives hypoxia-induced stem-like transition states and immune evasion in breast cancer
Ray Pillai, MD
Instructor NYU Grossman School of Medicine, New York, New York Autocrine LIF signaling: A novel therapeutic target to eliminate inflammatory and immunosuppressive cancer stem cells in LKB1 mutant lung adenocarcinoma
Amulya Sreekumar, PhD
Research Associate University of Pennsylvania, Philadelphia, Pennsylvania Residual breast cancer cells co-opt SOX5-driven endochondral ossification to maintain dormancy
Daniel Zabransky, MD, PhD
Assistant Professor Johns Hopkins University, Baltimore, Maryland Overcoming aging-driven barriers to effective immunotherapy in pancreatic cancer
